Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oncimmune Holdings PLC - Nottingham-based immunodiagnostics developer - Signs two further ImmunoInsights commercial contracts. One contract is with an unnamed US-based clinical-stage biopharmaceutical company, that develops cellular immunotherapies for cancer patients. Oncimmune will provide the customer with its biomarker discover platform SeroTag to identify autoantibodies. Second contract is with another US clinical-stage biopharmaceutical company which is developing immune system-related technologies.
No financial details are provided.
‘We are particularly excited by the signing of our first contract within the allogenic and CAR-NK market segment which we believe could open up a new opportunity for our services in the engineered cellular therapy space,’ says Chief Executive Officer Adam Hill.
Current stock price: 136.32 pence, up 8.4% on Friday
12-month change: down 42%
Copyright 2022 Alliance News Limited. All Rights Reserved.